Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (171-180 of 192) with videos related to

Pageof 20
Sort By:
Targeted Oncology|October 30, 2023
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance StatusKenji Morimoto, Tadaaki Yamada, Hayato Kawachi, et al.
Frontiers in Immunology|March 11, 2024
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50Shota Takei, Hayato Kawachi, Tadaaki Yamada, et al.
Clinical Lung Cancer|January 3, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424LShunichi Kataoka, Takehito Shukuya, Hiroshi Ohtsu, et al.
Investigational New Drugs|August 21, 2024
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohortYusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2024
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort studyNao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Oncoimmunology|December 16, 2024
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapyHayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, et al.
JTO Clinical and Research Reports|May 30, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <i>ALK</i>-Positive NSCLC in JapanYasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, et al.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
JTO Clinical and Research Reports|March 19, 2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter StudyAkito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, et al.
Pageof 20

Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
Targeted Oncology|October 30, 2023
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance StatusKenji Morimoto, Tadaaki Yamada, Hayato Kawachi, et al.
Frontiers in Immunology|March 11, 2024
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50Shota Takei, Hayato Kawachi, Tadaaki Yamada, et al.
Clinical Lung Cancer|January 3, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424LShunichi Kataoka, Takehito Shukuya, Hiroshi Ohtsu, et al.
Investigational New Drugs|August 21, 2024
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohortYusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2024
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort studyNao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Oncoimmunology|December 16, 2024
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapyHayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, et al.
JTO Clinical and Research Reports|May 30, 2023
A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With <i>ALK</i>-Positive NSCLC in JapanYasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, et al.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
JTO Clinical and Research Reports|March 19, 2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter StudyAkito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, et al.
Pageof 20